Patients who were first diagnosed with chronic subdural hematoma and after burr hole surgery.
Conditions
Interventions
Goreisan and carbazochrome sodium sulfonate hydrate and tranexamic aid were administered orally thrice daily to patients within at least 72 hours after surgery.
Sponsors
Hirata Koji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or more 2. First diagnosed with chronic subdural hematoma 3. Allocation within 72 hours after surgery 4. No plan for embolization to the middle meningeal artery 5. Written consent has been obtained from the individual or legal proxy
Exclusion criteria
Exclusion criteria: 1. After craniotomy or embolization of middle meningeal artery 2. Recurrence of chronic subdural hematoma 3. Patients with cerebrospinal fluid shunt 4. Patients with a history of hypersensitivity to any component of the study drug 5. Patients who have already received any of the study drugs 6. Those with hereditary fructose intolerance 7.Those in the acute phase of ischemic vascular disease 8. Patients with deep vein thrombosis 9. Patients under consumption coagulopathy or disseminated intravascular coagulation 10. Patients with thrombotic predisposition 11.Those on dialysis 12. Pregnant women 13. Patients who have received other study or investigational drugs for therapeutic purposes within three months of the scheduled administration of the study drug 14. Other patients which the physician deems unsuitable for enrollment in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the recurrence rate of hematoma. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. the duration of recurrence 2. hematoma volume on CT at 1day, 10days, 30days, 60days and 90days after surgery. | — |
Contacts
Public ContactKoji Hirata
University of Tsukuba Hospital
Outcome results
None listed